TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03975660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Measurement Device
Description: When participants request labor analgesia, the sensors of the pain measurement device (ROPA System \[CereVu Medical, Inc. San Francisco, CA\] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Measurement Device
Description: When participants request labor analgesia, the sensors of the pain measurement device (ROPA System \[CereVu Medical, Inc. San Francisco, CA\] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.
Study: NCT04425148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Alternating Current Stimulation (sham tACS)
Description: Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.
Study: NCT03057132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavilon Advanced Skin Protectant
Description: Cavilon Advanced Skin Protectant
Study: NCT01537250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500 mg placebol
Description: oral form,,once adily,7\~10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500 mg placebol
Description: oral form,,once adily,7\~10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin 3 tablets
Description: oral form,once daily,7\~10 days
Study: NCT01538446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modification of Prasugrel based on a biological assay
Description: Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel / clopidogrel
Description: fixed dose of prasugrel 5 mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verify Now
Description: Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
Study: NCT01364220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg tablet, once daily, for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet, once daily, for 14 days
Study: NCT03276702

Intervention type: PROCEDURE
Intervention: Re-biopsy
Description: For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.

Intervention type: OTHER
Intervention: Questionnaire
Description: Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
Study: NCT04354311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI
Description: Under steady state total intravenous anaesthesia with propofol and remifentanil at constant dosage, tetanus stimulation of the ulnar nerve was performed followed by orotracheal intubation. The variation of ANI and hemodynamic parameters as well as the somatic response associated with both maneuvers were collected.
Study: NCT01950039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaine
Description: Betaine or placebo administered orally in divided doses over 12 weeks
Study: NCT02301234

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg
Description: Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg
Description: Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib 100 mg
Description: Double-blind capsules taken twice daily for up to 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg Matching Placebo
Description: Double-blind capsules taken twice daily for up to 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg Matching Placebo
Description: Double-blind capsules taken twice daily for up to 16 weeks.
Study: NCT02911272

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-hour action line on WHO modified partograph
Description: observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
Study: NCT01950039

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally in divided doses over 3 months
Study: NCT06709599

Intervention type: OTHER
Intervention: Three-Week Strength and Conditioning Program
Description: Athletes train six days a week for three weeks, totaling approximately 15 hours of training per week. Training includes circuit training, weightlifting, technique drills, and sparring, designed to mimic typical MMA preparation.
Study: NCT00683592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00680524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based outreach
Description: Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
Study: NCT05397301

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled sedoanalgesia
Description: Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled sedoanalgesia
Description: Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine
Study: NCT06347809

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT01436448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics Lactobacillus Rhamnosus
Description: Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
Study: NCT04194151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: 1, 1.5 or 2 mg/kg of propofol according to the subgroup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: 1, 1.5 or 2 mg/kg of propofol according to the subgroup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: 1, 1.5 or 2 mg/kg of propofol according to the subgroup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: 1, 1.5 or 2 mg/kg of propofol according to the subgroup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: 1, 1.5 or 2 mg/kg of propofol according to the subgroup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: 1, 1.5 or 2 mg/kg of propofol according to the subgroup
Study: NCT03968016

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SYSMEX HLSCL
Description: Diagnostic device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYSMEX HLSCL
Description: Diagnostic device
Study: NCT04190927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Compounded topical estradiol and compounded topical progesterone in a carrier cream
Description: Apply topical compounded estradiol and progesterone in the amount prescribed twice daily for each day of the 28 day lunar or menstrual cycle. Repeat each cycle month. Make note of any AE's so that modifications in dosing can be made.
Study: NCT01280227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SiSom
Description: SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
Study: NCT02636673

Intervention type: PROCEDURE
Intervention: Sigmoid Resection

Intervention type: PROCEDURE
Intervention: Sigmoid Resection
Study: NCT03598309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin C3 complex®
Description: Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin C3 complex®
Description: Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza®
Description: Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza®
Description: Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
Study: NCT05007639

Intervention type: OTHER
Intervention: Public Health intervention programme
Description: The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).

Intervention type: OTHER
Intervention: No public Health intervention programme
Study: NCT00767208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose load
Description: oral ingestion of 13C labeled glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose load
Description: oral ingestion of 13C labeled glucose
Study: NCT05085847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Description: Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (\> 5 years each) experiences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
Study: NCT00655317

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
Study: NCT01648322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: subcutaneous injection given 1 per chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: subcutaneous injection given 1 per chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: subcutaneous injection given 1 per chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta® (pegfilgrastim)
Description: Single dose injection given once per chemotherapy cycle.
Study: NCT01706315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available
Study: NCT02408029

Intervention type: OTHER
Intervention: Observational study - no intervention
Study: NCT04479852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-624
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT03533569

Intervention type: PROCEDURE
Intervention: Intra-articular corticosteroid injection
Description: Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection

Intervention type: PROCEDURE
Intervention: Intra-articular corticosteroid injection
Description: Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection

Intervention type: PROCEDURE
Intervention: Intra-articular corticosteroid injection
Description: Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
Study: NCT02510248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-704
Description: JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AL-704
Study: NCT01310751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost nebuliser solusion
Description: 50 ng/kg/min inhalation for 10 minutes, q2h for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: 2 ml per session
Study: NCT04219904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study: NCT02911272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forewater amniotomy
Description: Forewater amniotomy at the vaginal examination confirming active phase labour
Study: NCT03272230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECOCAPTURE
Description: 45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Behavioral experimental tasks
Description: Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: STARKSTEIN APATHY SCALE (SAS) / DAS / MMSE / MADRS / EBI / MINI-SEA / FAB / HAD / MATTIS / HAYLING / STROOP / Verbal Span / Lexical verbal fluency / TMT / CDRS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICM_APATHY_TASKS
Description: Apathy experimental task

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: T1 / T2 / rs-fMRI / MS-DWI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neurohormonal mechanisms
Description: Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
Study: NCT03694002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT00655317

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
Study: NCT01489930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for \~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control/Combined training
Description: Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
Study: NCT03694002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT01516528

Intervention type: PROCEDURE
Intervention: Spirometry
Description: Assessment of lung function by spirometry
Study: NCT02911272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forewater amniotomy
Description: Forewater amniotomy at the vaginal examination confirming active phase labour

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-hour action line on WHO modified partograph
Description: observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
Study: NCT03276364

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Point-of-care ultrasound examination by pulmonary and critical care fellow
Study: NCT02710734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study: NCT02823327

Intervention type: GENETIC
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical chart review is performed